福他替尼抑制 COVID-19 患者血浆诱导的中性粒细胞胞外陷阱：一种潜在的治疗方法。
Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic.
机构信息
Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
United States Public Health Service Commissioned Corps, Rockville, Maryland, USA.
出版信息
J Infect Dis. 2021 Mar 29;223(6):981-984. doi: 10.1093/infdis/jiaa789.
Neutrophil extracellular traps (NETs) contribute to immunothrombosis and have been associated with mortality in coronavirus disease 2019 (COVID-19). We stimulated donor neutrophils with plasma from patients with COVID-19 and demonstrated that R406 can abrogate the release of NETs. These data provide evidence for how fostamatinib may mitigate neutrophil-associated mechanisms contributing to COVID-19 immunopathogenesis.
中性粒细胞胞外陷阱（NETs）有助于免疫血栓形成，并与 2019 年冠状病毒病（COVID-19）的死亡率有关。我们用 COVID-19 患者的血浆刺激供体中性粒细胞，并证明 R406 可以阻止 NETs 的释放。这些数据为福他替尼如何减轻与中性粒细胞相关的导致 COVID-19 免疫发病机制的机制提供了证据。
Zotero 插件